c5 (formerly EuroForum)will present Europe's first anti-corruption conference focused specifically on the pharmaceutical and life sciences industries. The increase in enforcement of the Foreign Corrupt Practices Act (FCPA) makes anti-corruption prevention an even higher priority than ever before. With record-setting sanctions involving well-known companies within the pharma and life sciences industries, global organisations must reassess their anti-corruption measures to prevent lapses that might lead to damaging and costly enforcement actions. Areas of practice specific to the pharmaceutical industry, such as drug discovery, clinical trials, sales and marketing of drugs, and close relationships with healthcare professionals, make pharmaceutical and life sciences companies particularly vulnerable to inadvertent FCPA violations.

WilmerHale partner, Paul A. von Hehn, will be a featured speaker at this event on the April 3rd session, and will speak on the topic of, "US and EU Perspective on How to Conduct an Internal Investigation – Dealing with the Troublesome Issues."